Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

NCT06694636 · tracked via the Priya Life Science China tracker

Sponsor

Zhongda Hospital

Phase

Not applicable

Started

2024-02-01

Last updated

2024-11-19

Condition(s) studied

Hepatocellular Carcinoma

Investigational drug(s) / intervention(s)

endovascular radiofrequency ablation and desympathetic nerve surgery

endovascular radiofrequency ablation and desympathetic nerve surgery: endovascular radiofrequency ablation and desympathetic nerve surgery

Study summary

Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.

Eligibility

Sex

ALL

Min age

25 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Clinically or pathologically confirmed hepatocellular carcinoma (HCC) * Locally progressed or distant metastatic unresectable advanced HCC * Progressed after second-line therapy * Agree to participate in the study and sign the informed consent form Exclusion Criteria: * Not suitable for ablation surgery * Pregnant, lactating and planning to become pregnant * Orthostatic hypotension * Mixed liver cancer * Intestinal obstruction * Obvious bleeding tendencies and hematologic diseases * Acute or severe systemic infection; * Stroke or transient ischemic attack (TIA) within two weeks; * Acute coronary syndrome within two weeks; * Evaluated to be not suitable for this trial by investigators

Primary outcome measure(s)

ORR — every month, up to 1 year
Objective Response Rate

Trial sites (1)

Facility	City	Region	Status
Zhongda Hospital	Nanjing	Jiangsu	Recruiting

More Zhongda Hospital trials in China

PyroEVs/PLIN3 Mediate Lipid Droplet-Mitochondrial Coupling in Sepsis Endothelial Injury Recruiting

A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy Active, not recruiting

Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026) Starting soon

SIRT Versus cTACE for Unresectable HCC (CHANCE2506) Recruiting

Epidural Spinal Cord Stimulation for Respiratory Recovery in Cervical SCI Recruiting

Other trials for the same condition

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing Recruiting

Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study Starting soon

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial Recruiting

HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06694636 on ClinicalTrials.gov ↗ ← All trials in China